Orforglipron Clinical Trials

2 actively recruiting trials across 1 location

No change since May 2026

Also known as: (LY3502970), LY3502970

Pipeline

Phase 3: 2

Top Sponsors

Eli Lilly and Company2

Indications

Atherosclerosis Cardiovascular Disease1
Osteoarthritis1
Heart Disease1
Chronic Kidney Disease1
Arthritis1

Other1 trial

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Phase 3

Phoenix, Arizona1 trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Arizona Research Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.